Related Experiment Video

Updated: Aug 15, 2026

Three-Dimensional (3D) Tumor Spheroid Invasion Assay
12:19

Three-Dimensional (3D) Tumor Spheroid Invasion Assay

Published on: May 1, 2015

Type 1 protein tyrosine kinases in breast carcinoma: a review

Zhenhe Suo1, Jahn M Nesland

  • 1Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Norway. zhenhe.suo@labmed.uio.no

Ultrastructural Pathology
|August 20, 2002
PubMed

Insights

The study examines type 1 protein tyrosine kinases in breast cancer. Reduced c-erbB-4 expression correlates with better outcomes, suggesting its analysis for targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Type 1 protein tyrosine kinases (EGFR, c-erbB-2, c-erbB-3, c-erbB-4) are key in breast tumors.
  • c-erbB-2 overexpression indicates poor prognosis; EGFR enhances this effect.
  • c-erbB-4 expression is reduced in breast carcinomas compared to normal tissue.

Purpose of the Study:

  • To analyze the expression patterns of type 1 protein tyrosine kinases in breast carcinomas.
  • To investigate the clinical significance of c-erbB-4 expression in breast cancer prognosis.
  • To highlight the importance of c-erbB-4 analysis for targeted therapies.

Main Methods:

  • Analysis of protein and mRNA expression levels of EGFR, c-erbB-2, c-erbB-3, and c-erbB-4 in breast tumor samples.
  • Correlation of receptor expression with clinical outcomes and patient prognosis.
  • Comparative analysis between carcinoma and normal breast epithelial tissues.

Main Results:

  • Overexpression of c-erbB-2 is linked to poor prognosis in breast cancer.
  • EGFR overexpression synergistically impacts the clinical effect of c-erbB-2.
  • Reduced c-erbB-4 expression in carcinomas is associated with better clinical outcomes.

Conclusions:

  • c-erbB-4 expression analysis is crucial when considering EGFR and c-erbB-2 antibody therapies.
  • Understanding dysregulated receptor expression mechanisms requires studying adaptor proteins.
  • Targeted therapeutic strategies in breast cancer should account for differential c-erbB-4 expression.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...